//HER2-low breast cancer
Beware HER2-low breast cancer — it's subtle, but we're watching. 
With emerging targeted therapies, especially antibody drug conjugates like trastuzumab deruxtecan, we're hitting back with precision. 
HER2-low is no longer out of reach — we're turning detection into direction.
